Data for ST002354   

(Analysis AN003842): Average values per metabolite and experimental factor (Units:mg/g tissue)

Metabolite structureAll dataF1F2F3F4F5F6F7F8F9F10F11F12F13F14F15F16F17F18F19F20F21F22F23F24F25F26F27F28F29F30F31F32
Arachidic acid
2.41 3.52 2.26 2.28 3.52 3.32 2.99 3.91
Arachidonic acid
1.34 1.60 0.89 0.85 1.12 0.58 1.44 1.00
Dihomo-g-linolenic acid
0.06 0.10 0.04 0.03 0.03 0.02 0.06 0.04
Docosadienoic acid
0.04 0.06 0.03 0.02 0.04 0.03 0.04 0.03
Docosahexaenoic acid
0.24 0.34 0.32 0.38 0.53 0.44 0.39 0.59
Docosanoic acid (Behenic acid)
1.62 2.54 2.30 1.85 4.17 2.93 3.21 2.96
Docosapentaenoic acid (n-3)
0.03 0.03 0.12 0.14 0.29 0.27 0.17 0.26
Docosapentaenoic acid (n-6)
0.04 0.05 - - - - - -
Docosatetraenoic acid
0.15 0.17 0.04 0.03 0.04 0.02 0.08 0.06
Docosatrienoic acid
0.07 0.10 0.03 0.03 0.04 0.03 0.06 0.04
Docosenoic acid
2.08 2.92 2.94 2.72 4.94 2.78 3.22 2.87
Dodecanoic acid
2.16 - - 4.13 5.51 4.72 3.22 6.51
Eicosadienoic acid
0.65 1.19 0.50 0.44 0.85 0.76 0.93 1.00
Eicosapentaenoic acid
0.09 0.09 0.39 0.49 1.40 1.55 0.49 1.07
Eicosenoic acid
0.57 1.05 0.64 0.71 1.24 2.18 1.00 3.01
Heptadecanoic acid
1.21 1.74 1.46 1.76 2.46 1.98 1.70 2.56
Heptadecenoic acid
0.17 0.27 0.27 0.36 0.62 0.72 0.33 0.77
Hexacosanoic acid
0.17 0.28 0.25 0.26 0.51 0.23 0.23 0.34
Hexacosenoic acid
0.02 0.04 0.05 0.05 0.34 0.21 0.06 0.24
Lignoceric acid
1.19 1.84 1.84 1.52 3.90 2.21 2.26 2.15
Linoleic acid
23.19 50.23 32.83 55.15 71.97 74.20 51.15 124.88
Linolenic acid (alpha)
0.09 0.09 0.06 0.07 0.09 0.12 0.07 0.22
Mead acid
0.03 0.06 0.04 0.04 0.05 0.05 0.06 0.05
Myristic acid
1.22 1.47 3.11 4.02 4.39 5.23 2.48 6.83
Nervonic acid
0.46 0.79 0.76 0.65 2.03 1.42 0.93 1.61
Octadecatetraenoic acid (Stearidonic acid)
- - - - 0.00 0.03 - 0.02
Oleic acid
14.16 28.86 20.14 32.05 38.62 61.41 30.52 74.27
Palmitic acid
16.91 26.84 26.10 35.56 41.31 40.05 29.53 47.28
Palmitoleic acid
2.05 4.38 7.14 16.49 17.25 32.06 8.10 32.65
Pentadecanoic acid
1.50 1.71 2.27 2.23 2.94 1.92 1.87 2.79
Stearic acid
44.99 55.42 44.47 46.06 64.86 49.69 52.60 56.66

Factors:

F1Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma
F2Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon
F3Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma
F4Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon
F5Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma
F6Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon
F7Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma
F8Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon
F9Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma
F10Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon
F11Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma
F12Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon
F13Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma
F14Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon
F15Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma
F16Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon
F17Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma
F18Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon
F19Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma
F20Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon
F21Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma
F22Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon
F23Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma
F24Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon
F25Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma
F26Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon
F27Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma
F28Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon
F29Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma
F30Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon
F31Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma
F32Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon
  logo